メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ムコ多糖症II(MPS II、ハンター症候群):世界の治験レビュー

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Global Clinical Trials Review, H2, 2017

発行 GlobalData 商品コード 305091
出版日 ページ情報 英文 56 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.61円で換算しております。
Back to Top
ムコ多糖症II(MPS II、ハンター症候群):世界の治験レビュー Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Global Clinical Trials Review, H2, 2017
出版日: 2017年12月28日 ページ情報: 英文 56 Pages
概要

当レポートでは、ムコ多糖症II(MPS II)に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主な先進国・新興国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んで、概略以下の構成でお届けします。

目次

イントロダクション

  • ムコ多糖症II(MPS II、ハンター症候群)
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要国における治験件数
    • 欧州上位5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:代謝障害全体に対する比率

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:代謝障害全体に対する比率

E7諸国での治験件数:フェーズ(相)別

E7諸国での治験件数:進捗状況別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

  • ムコ多糖症II治療薬の治験に参加している上位企業

有望な薬剤

治験のプロファイル

  • 代表的企業の治験の概要
    • Shire Plc
    • Green Cross Holdings Corporation
    • Medical Resources International Pte Ltd.
    • GlaxoSmithKline plc
    • Cytomedix, Inc.
    • ArmaGen Technologies, Inc.
  • 代表的な研究機関・病院の治験の概要
    • University of Minnesota
    • 東海大学医学部
    • University of Rostock
    • Clinical and Translational Science Institute
    • The University of Chicago
    • Eunice Kennedy Shriver National Institute of Child Health and Human Development

5つの代表的な治験のプロファイル

付録

図表一覧

目次
Product Code: GDHC4803CTIDB

GlobalData's clinical trial report, "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Global Clinical Trials Review, H2, 2017" provides an overview of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) clinical trials scenario. This report provides top line data relating to the clinical trials on Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Five Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) to Genetic Disorders Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) to Genetic Disorders Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Clinical Trials 28
  • Prominent Drugs 29
  • Clinical Trial Profile Snapshots 30

Appendix 54

  • Abbreviations 54
  • Definitions 54
  • Research Methodology 55
  • Secondary Research 55
  • About GlobalData 56
  • Contact Us 56
  • Source 56

List of Tables

List of Tables

  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
  • Proportion of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) to Genetic Disorders Clinical Trials, G7 Countries (%), 2017* 15
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) to Genetic Disorders Clinical Trials, E7 Countries (%), 2017* 18
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics, Global, Clinical Trials by Phase, 2017* 21
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29
Back to Top